07:00 , Sep 22, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Phosphoinositide 3-kinase class 2 subunit β polypeptide (PI3KC2B); myotubularin 1 (MTM1); phosphatidylinositol-3-phosphate (PI3P)

Musculoskeletal disease INDICATION: Musculoskeletal Mouse and zebrafish studies suggest inhibiting PI3KC2B could help treat myotubular myopathy, which is caused by mutations in MTM1. In a mouse model of the disease, muscle-specific knockout of PI3KC2B or a PI3K...
07:00 , May 7, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Click chemistry screen for peptides binding inaccessible mutations

Drug platforms TECHNOLOGY: Peptides Click chemistry-based screening could identify peptide inhibitors of mutant proteins. A peptide epitope containing the mutation was modified with an alkyne group amenable to azide-alkyne click chemistry, and screened against a library of...
08:00 , Jan 22, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Phosphoinositide 3-kinase (PI3K) catalytic subunit β polypeptide (PIK3CB; p110-β); PI3K catalytic subunit α polypeptide (PIK3CA; p110α); phosphati

Cancer INDICATION: Cancer Cell culture and mouse studies suggest inhibiting PIK3CB could circumvent resistance to PIK3CA inhibitors in cancer. In a panel of human breast cancer cell lines sensitive to PIK3CA inhibitors, development of resistance to PI3KCA...
08:00 , Jan 6, 2011 |  BC Innovations  |  Cover Story

Inositol insulin insight

A lack of druggable targets in the insulin-Akt pathway has made increasing insulin signaling an uphill struggle for metabolic disease companies. Indeed, there are no approved drugs that directly modulate Akt or other intracellular components...
08:00 , Nov 11, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Phosphatidylinositol 3,4,5-triphosphate (PIP3); phosphoinositide 3-kinase (PI3K); 3-phosphoinositide dependent protein kinase-1 (PDPK1); protein kinase B (PKB; Akt)...
08:00 , Feb 27, 2006 |  BioCentury  |  Product Development

Pathway complexity

Pathway complexity The rationale for developing Herceptin was straightforward: by inactivating the HER2 cell surface receptors overexpressed in certain breast cancer cells, the cascade leading to tumorigenesis can be halted. But it turned out not all...
08:00 , Mar 4, 2002 |  BC Week In Review  |  Company News

Roche other research news

Researchers published in Science evidence that Akt ( protein kinase B) modulates growth deregulation caused by the loss of the function of the tumor suppressor phosphoinisotide phosphatase PTEN. In Drosophila, genetic mutation of Akt...